References
- Armangue T, Titulaer MJ, Màlaga I, et al. Pediatric anti-N-methyl-D-Aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162:850–856.
- Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36.
- Wright S, Hacohen Y, Jacobson L, et al. N-methyl-D-aspartate receptor antibody mediated neurological disease: results of a UK-based surveillance study in children. Arch Dis Child. 2015;100:521–526.
- Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83:166–177.
- Boesen MS, Born AP, Lydolph MC, et al. Pediatric autoimmune encephalitis in Denmark during 2011-17: A nationwide multicenter population-based cohort study. Eur J Paediatr Neurol. 2019;23:639–652.
- Konuskan B, Yildirim M, Topaloglu H, et al. Clinical presentation of anti-N-methyl-d-aspartate receptor and anti-voltage-gated potassium channel complex antibodies in children: A series of 24 cases. Eur J Paediatr Neurol. 2018;22:135–142.
- Dalmau J, Gleichman AJ, Hughes EG, et al. Anti–NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–1098.
- Ho AC, Chan SH, Chan E, et al. Anti-N-methyl-d-aspartate receptor encephalitis in children: incidence and experience in Hong Kong. Brain Dev. 2018;40:473–479.
- Zhao J, Wang C, Xu X, et al. Coexistence of autoimmune encephalitis and other systemic autoimmune diseases. Front Neurol. 2019;10:1142.
- Hsu YW, Juan CJ, Lee JT, et al. Anti-N-Methyl-D-aspartate-receptor encephalitis complicated with antiphospholipid syndrome and cerebral venous thrombosis. J Clin Rheumatol. 2017;23:294–295.
- Singh G, Prabhakar D. Neuropsychiatric Presentation of Anti-N-Methyl-D-Aspartate receptor encephalitis with comorbid sinus venous thrombosis. Prim Care Companion CNS Disord. 2016;18:6.
- Sakamoto H, Hirano M, Samukawa M, et al. Details of treatment-related difficulties in men with anti-N-methyl-D-aspartate receptor encephalitis. Eur Neurol. 2013;69:21–26.
- Lim JA, Lee ST, Kim TJ, et al. Frequent rhabdomyolysis in anti-NMDA receptor encephalitis. J Neuroimmunol. 2016;298:178–180.
- Goenka A, Jain V, Nariai H, et al. Extended clinical spectrum of AntieN-Methyl-D-Aspartate receptor encephalitis in children: a case series. Pediatr Neurol. 2017;72:51–55.
- Pruetarat N, Netbaramee W, Pattharathitikul S, et al. Clinical manifestations, treatment outcomes, and prognostic factors of pediatric anti-NMDAR encephalitis in tertiary care hospitals: A multicenter retrospective/prospective cohort study. Brain Dev. 2019;41:436–442.
- Qu XP, Vidaurre J, Peng XL, et al. Seizure Characteristics, outcome, and risk of epilepsy in pediatric Anti-N-Methyl-d-Aspartate receptor encephalitis. Pediatr Neurol. 2020;105:35–40.
- Do Valle DA, Galeazzi JSP, Machado MR, et al. Clinical variability of children with anti-N-methyl-D-aspartate receptor encephalitis in southern Brazil: a cases series and review of the literature. Neurol Sci. 2019;40:351–356.
- Wang Y, Zhang W, Yin J, et al. Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: clinical features, treatment, influencing factors, and outcomes. J Neuroimmunol. 2017;312:59–65.
- van de Riet EHCW, Esseveld MM, Cuypers L, et al. Anti-NMDAR encephalitis: a new, severe and challenging enduring entity. Eur Child Adolesc Psychiatry. 2013;22:319–323.
- Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study. Lancet Neurol. 2013;12:157–165.
- Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11–18.
- Nosadini M, Granata T, Matricardi S, et al. Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2019;61:1101–1107.
- Rajpurkar M, Biss T, Amankwah EK, et al. Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review. Thromb Haemost. 2017;117:1199–1207.
- Engbers MJ, Blom JW, Cushman M, et al. van Hylckama Vlieg A. The contribution of immobility risk factors to the incidence of venous thrombosis in an older population. J Thromb Haemost. 2014;12:290–296.
- Ramiz S, Rajpurkar M. Pulmonary Embolism in Children. Pediatr Clin North Am. 2018;65:495–507.
- Maramattom BV, Jacob A. N-methyl D-aspartate receptor encephalitis: A new addition to the spectrum of autoimmune encephalitis. Ann Indian Acad Neurol. 2011;14:153–157.
- Smith JH, Dhamija R, Moseley BD, et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. Arch Neurol. 2011;68:1069–1072.
- Iizuka T, Kaneko J, Tominaga N, et al. Association of progressive cerebellar atrophy with long-term outcome in patients with Anti-N-Methyl-d-Aspartate receptor encephalitis. JAMA Neurol. 2016;73:706–713.
- Kurian M, Lalive PH, Dalmau JO, et al. Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. Arch Neurol. 2010;67:118–121.
- Wada T, Kadoya M, Nakagawa K, et al. Rituximab therapy and clinical management in anti-NMDA receptor antibody encephalitis refractory to first-line immunotherapy: japanese case series. J Neurol Sci. 2017;381:911.
- Garré J, Sprengers M, Van Melkebeke D, et al. EBV-NMDA double positive encephalitis in an immunocompromised patient. J Neurol Sci. 2019;396:76–77.
- Ishiura H, Matsuda S, Higashihara M, et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology. 2008;71:1921–1923.